Early research (Phase 1)Not Yet RecruitingNCT07617012
What this trial is testing
The Safety, Tolerability, and Efficacy of Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P).
Who this might be right for
the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P)
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. 3